Drugs / JSM6427
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00536016 | Sep 2007 → Dec 2008 | macular degeneration | Jerini Ophthalmic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JSM6427 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00536016 ↗ |
| Action | Inhibit | “JSM6427 can lead to the inhibition and regression of choroidal neovascularization” NCT00536016 ↗ |
| Route | Intravitreal | “Weekly intravitreal injections for up to 4 weeks” NCT00536016 ↗ |